Cell:可增加睾丸癌风险的遗传变异

2013-10-14 佚名 手牵手博客站

日前,来自英国牛津大学等机构的科学家们找到了一种会极大增加睾丸癌患病风险的常见突变,并提出了该种突变完成功能的一种新机制,由此研究人员还解释了,为什么尽管这种突变具有致命性,仍然会通过自然选择,成为浅肤色人群的常见突变。 研究人员在《细胞》杂志上报告称,了解癌症遗传学分子机制,将有助于新药研发,这些研究能用于开发预测癌症,尤其是恶性肿瘤风险的检测技术,而且这也能帮助医

日前,来自英国牛津大学等机构的科学家们找到了一种会极大增加睾丸癌患病风险的常见突变,并提出了该种突变完成功能的一种新机制,由此研究人员还解释了,为什么尽管这种突变具有致命性,仍然会通过自然选择,成为浅肤色人群的常见突变。

研究人员在《细胞》杂志上报告称,了解癌症遗传学分子机制,将有助于新药研发,这些研究能用于开发预测癌症,尤其是恶性肿瘤风险的检测技术,而且这也能帮助医师们了解癌症的预后可能,提高疾病治疗效果。【原文下载】

研究人员分析了包含 62,567 个癌症相关 SNPs 的数据库,从中寻找会改变著名的抑癌基因:p53 激活其靶标基因能力的突变,p53 是迄今发现与人类肿瘤相关性最高的基因。在短短的十多年里,人们对 p53 基因的认识经历了癌蛋白抗原,癌基因到抑癌基因的三个认识转变,目前的研究指出 p53 蛋白能与其它多种蛋白相互作用,其基因发生突变,都可以导致正常生物功能的丧失。

在这项研究中,科学家发现了能提升 p53 与一个关键应答元件相关性的突变,并指出这个特殊的 SNP 与睾丸癌的患病风险具有紧密联系。这一 SNP 能激活一种称为KIT配体(KITLG)的蛋白产生。研究表明, p53 激活 KITLG 能促进细胞的增殖。因此这项研究表明, SNP 能显着提高 p53 基因调控各种细胞中 KITLG 的能力,这也就是说“这个特殊的突变能帮助睾丸干细胞在出现了 DNA 损伤的情况下,依然生长,在正常细胞中,由于这种损害可能会导致癌症,因此不应该再继续生长了。”


原文检索

Jorge Zeron-Medina, Xuting Wang, Emmanouela Repapi, Michelle R. Campbell, Dan Su, Francesc Castro-Giner, Benjamin Davies, Elisabeth F.P. Peterse, Natalia Sacilotto, Graeme J. Walker, Tamara Terzian, Ian P. Tomlinson, Neil F. Box, Nicolai Meinshausen, Sarah De Val, Douglas A. Bell, Gareth L. Bond.A Polymorphic p53 Response Element in KIT Ligand Influences Cancer Risk and Has Undergone Natural Selection.Cell, 2013 October 10.【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
    2014-09-11 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
    2014-04-24 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]
    2013-10-16 zhangph
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958930, encodeId=c0401958930cb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Sep 11 17:29:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868691, encodeId=9c29186869102, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 12 09:29:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061402, encodeId=67ff20614021a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 24 23:29:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342284, encodeId=efcf1342284ae, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368303, encodeId=fe4d136830308, content=<a href='/topic/show?id=2fa7e3068b9' target=_blank style='color:#2F92EE;'>#睾丸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73068, encryptionId=2fa7e3068b9, topicName=睾丸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377163, encodeId=bc5e13e71631e, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Oct 16 00:29:00 CST 2013, time=2013-10-16, status=1, ipAttribution=)]

相关资讯

Nat Genet :科学家发现五种睾丸癌基因

德国汉诺威医学院5月21日宣布,研究人员发现了促使睾丸肿瘤形成的5种基因突变。这一发现将有助于今后睾丸癌的防治。 睾丸癌多出现在某一特定家族。这意味着,遗传因素对肿瘤产生起到促进作用。经调查,德国汉诺威医学院等机构的研究人员发现了总计5种有助于肿瘤形成的基因突变,并将研究报告发表在英国《自然—遗传学》和《人类分子遗传学》杂志上。 “这一突破由众多科学家通过紧密国际合作得来,也更好地帮助我们了解

Cancer:大麻或增加睾丸癌风险

近日,来自南加利福尼亚大学(USC)的研究者发现了大麻使用和患特定类型睾丸癌之间的关系,相关研究成果刊登在了近日的国际杂志Cancer上。文章中,研究者描述了大麻对于睾丸细胞潜在的癌症诱发效应。 睾丸癌是15至45岁男性常见的一种癌症,而且其是越来越常见的一种恶性肿瘤。因此研究者试图去研究其与患者暴露的环境是否有某种潜在的关系。为了观察大麻的使用是否是睾丸癌诱发的一个因素,研究者分析了163位被

AJHG:遗传拷贝数变异和睾丸癌风险直接相关

遗传机制在癌症的发展和进程中扮演着至关重要的作用,但是特定遗传突变引发的某种癌症的分子机制目前并不清楚,进一步说,任何癌症和名为拷贝数突变(CNVs)的遗传突变没有关系。如今,刊登在国际杂志The American Journal of Human Genetics 上的一篇文章揭示了CNVs和睾丸癌风险直接相关,CNVs和乳腺癌及结肠癌却没有关联。 一些癌症,诸如乳腺癌或者结肠癌是由上一代的突

NAT GENET :影响睾丸癌的12个遗传变异

6月《自然—遗传学》上的两篇文章报告了与睾丸癌有关的12种新的危险遗传变异的发现。 睾丸生殖细胞肿瘤是年轻人中最常见的一种癌症,发病峰值处于25到34岁之间。 Katherine Nathanson等人对睾丸生殖细胞肿瘤的6项全基因组关联研究进行了元分析,以及后续六个额外样品的副本检测。他们发现了4个新的染色体区域与该疾病的风险增加有关。在另外一项实验中,Clare Turnbull等人则对一